EHA 2022 | Phase II study of epcoritamab in R/R LBCL
Catherine Thieblemont, MD, PhD, Saint-Louis University Hospital, Paris, France, gives an overview of the results of a Phase II study evaluating subcutaneous epcoritamab dose expansion in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) (NCT03625037). The study reported impressive efficacy and mild toxicity. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Transcript (edited for clarity)
Yesterday I presented the epcoritamab bispecific result. This is the first result reported in relapsed/refractory large B-cell lymphoma. It’s a Phase II trial with different subtypes of large B-cell lymphoma in the relapsed and refractory setting, and the result in these populations showed that the overall response rate is 63% and the complete response rate, 39%. In these populations of heavily pre-treated patients, these results are really impressive...
Yesterday I presented the epcoritamab bispecific result. This is the first result reported in relapsed/refractory large B-cell lymphoma. It’s a Phase II trial with different subtypes of large B-cell lymphoma in the relapsed and refractory setting, and the result in these populations showed that the overall response rate is 63% and the complete response rate, 39%. In these populations of heavily pre-treated patients, these results are really impressive. With a toxicity profile which is very mild, mostly grade one and two in terms of CRS, and only 10 patients out of the 157 patients included have presented ICANS. The ICANS were for nine of them, grade one and two, and we observed only one patient with grade five ICANS, but with a lot of co-founding factors for these patients. So in conclusion, epcoritamab subcutaneous is a really impressive bispecific antibody, CD20, CD3, in this cohort of patients with relapsed/refractory large B-cell lymphoma.
Read more...
Disclosures
Research Funding: Hospira, Roche, Bristol Myers Squibb/Celgene; Consultancy: AbbVie, Cellectis, Amgen, Kite, Roche, Bristol Myers Squibb/Celgene, Novartis, Gilead Sciences; Honoraria: AbbVie, Bayer, Cellectis, Amgen, Incyte, Kite, Takeda, Janssen, Novartis, Gilead Sciences; Membership on an entity’s Board of Directors or advisory committees: AbbVie, Cellectis, Amgen, Incyte, Kite, Takeda, Janssen, Roche, Bristol Myers Squibb/Celgene, Novartis, Gilead Sciences; Other: Travel, Accommodations, Expenses: AbbVie, Cellectis, Amgen, Kite, Roche, Bristol Myers Squibb/Celgene, Novartis, Gilead Sciences
